Literature DB >> 1873499

Serodiagnosis of cancer using porcine carboxypeptidase A as an animal antigen recognized by human monoclonal antibody HB4C5.

S Hashizume1, K Mochizuki, M Kamei, K Kuroda, M Kato, S Sato, K Yasumoto, H Nakahashi, K Tsuchimoto, M Muraoka.   

Abstract

Protein from hog which is recognized by human monoclonal antibody (HB4C5), generated from a patient with large cell lung carcinoma, was identified as carboxypeptidase A by comparison of the protein with carboxypeptidase A in enzymatic activity, immunologic reactivity, and amino acid sequence. Carboxypeptidase A activity was also found in human cancer tissue, and purified antigen from cancer tissue recognized by the antibody HB4C5 was reacted with rabbit anti-carboxypeptidase A serum, indicating that carboxypeptidase A is an antigen of HB4C5. Since large amounts of carboxypeptidase A can be obtained from porcine sources, a simple method for its purification was established. The fraction which was most reactive with HB4C5 was obtained from acetone powder of porcine pancreas by successive applications of water extraction, ammonium sulfate precipitation, trypsin treatment, and Mono Q column chromatography. Its apparent molecular weight was 40,000, according to SDS polyacrylamide gel electrophoresis. When the reactivity of IgG in sera with the purified carboxypeptidase A was measured, the detection rates for lung, ovary, larynx, uterus, and liver cancer were more than 50%, while the rates for stomach and breast cancer were around 30%, and pancreatic cancer, benign diseases, and normal controls were minimally detected.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1873499

Source DB:  PubMed          Journal:  Hum Antibodies Hybridomas        ISSN: 0956-960X


  5 in total

1.  Altered reactivity of immunoglobulin produced by human-human hybridoma cells transfected by pSV2-neo gene.

Authors:  H Tachibana; K Akiyama; S Shirahata; H Murakami
Journal:  Cytotechnology       Date:  1991-07       Impact factor: 2.058

2.  Building high affinity human antibodies by altering the glycosylation on the light chain variable region in N-acetylglucosamine-supplemented hybridoma cultures.

Authors:  H Tachibana; J Y Kim; S Shirahata
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

3.  Modified antigen-binding of human antibodies with glycosylation variations of the light chains produced in sugar-limited human hybridoma cultures.

Authors:  H Tachibana; K Jiyoun; K Taniguchi; Y Ushio; K Teruya; K Osada; Y Inoue; S Shirahata; H Murakami
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-03       Impact factor: 2.416

4.  Improvement of antigen binding ability of human antibodies by light chain shifting.

Authors:  T Siripen; H Tachibana; Y Katakura; S Shirahata
Journal:  Cytotechnology       Date:  1997-11       Impact factor: 2.058

5.  Changes of monosaccharide availability of human hybridoma lead to alteration of biological properties of human monoclonal antibody.

Authors:  H Tachibana; K Taniguchi; Y Ushio; K Teruya; K Osada; H Murakami
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.